Chair and Moderator, Olalekan Oluwole, MBBS, MD, Veronika Bachanova, MD, PhD, Heather Landau, MD, and David L. Porter, MD, prepared a useful Practice Aid pertaining to CAR-T therapy for this CME activity titled “The Time Is Now for Outpatient CAR-T: Essential Infrastructure, Lessons From Transplant, and New Evidence.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3XpD8LK. CME credit will be available until March 15, 2024.

1. Resources for Planning an Outpatient CAR-T Initiative
Full abbreviations, accreditation, and disclosure information available at PeerView.com/NEC40
1. Gatwood KS et al. EJHaem. 2021;3:54-60.
Flow Chart Illustrating the Framework of Outpatient CAR-T Administration1
New patient consult
with history/physical
and approval
Apheresis and cell
manufacturing
Bridging
chemotherapy
Daily clinic visits
± after-hours
telemedicine visits
(x7-14 days)
2-3x weekly clinic
visits (through day 30
postinfusion)
Transition back
to primary
hematologist/
oncologist
Lymphodepleting
chemotherapy
Cell infusion
• Telemedicine
• Wearable monitoring devices
Google Store Apple Store
Currently available
tools for assessing
toxicity, such as
the CARTOX app,
can be applied to
outpatient settings